f66ÓÀÀÖÖйú-¿ÆÑ§¼Ò½Òʾ1990ÖÁ2019ÄêÈ«Çò¸ßѪѹ»¼²¡ÂÊÇ÷ÊÆ
2026-03-20 11:46:22
¿ÆÑ§¼ÒÕ¹ÏÖ1990ÖÁ2019ÄêÈ«ÊÀ½ç¸ßѪѹ»¼²¡ÂÊÇ÷Ïò
ÈÕÆÚ£º2021-09-17 À´Àú£º±¾Õ¾ ¹©¸å£ºÒ½Ò©ÉúÎï¼¼ÄÜ´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ
µÍ¼¶ÎÀÉú±£½¡ÖпÉÒÔÔç·¢Ã÷¸ßѪѹµÄ²¡·¢£¬ÇÒÆä½ÚÖÆ³É±¾½ÏµÍ¡£¾ß±¸¿É±ÈÐԵĸßѪѹ»¼²¡³Ðµ£Êý¾Ý¶ÔÓÚÎÀÉúÌåϵµÄÏîÄ¿¼Æ»®¾ß±¸Òýµ¼ÒâÒå¡£½üÈÕ£¬¹ú¼Ê·Ç¸ÐȾÐÔ¼²²¡É˺¦ÒòËØÐ×÷×飨NCD Risk Factor Collaboration£©ÓÚ¡¶Lancet¡·ÆÚ¿¯ÉÏ·¢±íÁËÒ»Ïî1990ÖÁ2019ÄêÈ«ÊÀ½ç200¸ö¹ú¶È¼°µØÓòµÄ¸ßѪѹ»¼²¡»·¾³Ñо¿£¬ÌâΪ£ºWorldwide trends in hypertension prevalenceand progress in treatment and control from 1990 to 2019: a pooled analysis of1201 population-representative studies with 104 million participants¡£ Ñо¿ÍŶӷ¢Ã÷£¬2019Ä꣬ȫÊÀ½ç30-79Ëê³ÉÈË´ºÇï±ê»¯»¼²¡ÂÊÅ®ÐÔΪ32%£¨95%¿ÉÍÐÇø¼ä£º30%-34%£©£¬ÄÐÐÔΪ34%£¨95%¿ÉÍÐÇø¼ä£º32%-37%£©£»1990Ä꣬ŮÐÔΪ32% (95%¿ÉÍÐÇø¼ä£º30%¨C35%)£¬ÄÐÐÔΪ32% (95%¿ÉÍÐÇø¼ä£º30%¨C35%)£¬Á½¸öʱ¼äµã¸ßѪѹ»¼²¡ÂÊÏàËÆ¡£ÒòΪÈË¿ÚÔö¼ÓÓëÈË¿ÚÀÏÁ仯£¬30-79Ëê³ÉÈ˸ßѪѹ»¼Õß¾ø¶ÔÓÚÊýÄ¿´Ó1990Äêµ½2019Äê·ÁËÒ»·¬¡£´Ó1990ÄêµÄ3.31ÒÚÅ®ÐÔ£¨95%¿ÉÍÐÇø¼ä£º3.06-3.59£©¼°3.17ÒÚÄÐÐÔ£¨95%¿ÉÍÐÇø¼ä£º2.92-3.44£©Ôö³¤µ½2019ÄêµÄ6.26ÒÚÅ®ÐÔ£¨95%¿ÉÍÐÇø¼ä£º5.84-6.68£©¼°6.52ÒÚÄÐÐÔ£¨95%¿ÉÍÐÇø¼ä£º6.04-f66ÓÀÀÖÖйú-6.98£©¡£ 2019Ä꣬¸ßѪѹ»¼ÕߵĽÚÖÆÂÊ£¨ÑªÑ¹½ÚÖÆÓÚ140/90ÃÃÃÃHgÈçϵÄÕ¼±È£©Å®ÐÔΪ23%£¨95%¿ÉÍÐÇø¼ä£º20%-27%£©£¬ÄÐÐÔΪ18%£¨95%¿ÉÍÐÇø¼ä£º16%-21%£©¡£ÓÚÄá²´¶û¡¢Ó¡¶ÈÄáÎ÷ÑÇÒÔºÍÈö¹þÀÒÔÄÏ·ÇÖÞ¼°ÄêÒ¹ÑóÖÞµÄһЩ¹ú¶È£¬Å®ÐÔµÄÒ½ÖÎÂʲ»µ½25%£¬ÄÐÐÔµÄÒ½ÖÎÂʲ»µ½20%¡£±±·Ç¡¢ÖÐÑÇ¡¢ÄÏÑǼ°¶«Å·µÄһЩ¹ú¶ÈµÄÄÐÐÔ½ÚÖÆÂʵÍÔÚ10%¡£Ñо¿·¢Ã÷£¬×Ô1990ÄêÒÔÀ´£¬ÄêÒ¹´ó¶¼¹ú¶ÈµÄ¸ßѪѹҽÖμ°½ÚÖÆÂÊÓÐËùÌá¸ß£¬µ«Èö¹þÀÒÔÄÏ·ÇÖÞ¼°ÄêÒ¹ÑóÖÞµÄÄêÒ¹´ó¶¼¹ú¶ÈÏÕЩûÓб仯¡£ÓÚ¸ßÊÕÈë¹ú¶È¡¢ÖÐÅ·¡¢ÖÐÉÏÊÕÈë¹ú¶ÈÖУ¬¸ßѪѹ³Ðµ£ºÍ½ÚÖÆ¸ÄÉÆ·ù¶È×îÄêÒ¹¡£ ÂÛÎÄÁ´½Ó£ºhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01330-1/fulltext#%20 ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶Lancet¡·ÆÚ¿¯£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È£¬½ö¹©²Î¿¼¡£-f66ÓÀÀÖÖйú-

¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……
.png)
.jpg)